Long term investing in the stock market often gives surprising results. If you identify the right company, even your small amount can turn into crores. One such miraculous performance has been done by the shares of Cupid Ltd. This company, which manufactures male and female condoms, has showered money on its investors. In the last three years, this stock has given an incredible return of 8,700 percent. If you understand in simple language, the investor who had invested only one lakh rupees in this company in July 2023, today the value of his holding has become Rs 87 lakh. On Tuesday also a rise of 5% was seen in this stock. Around 2 pm it was trading at Rs 217.99 on the National Stock Exchange (NSE).
This magical journey started with just Rs 2.5
In July 2023, the price of this share was only Rs 2.5 per share. Today it has crossed Rs 217. Even amidst the ups and downs of the market, its pace is showing no sign of stopping. Even though there has been a slight decline of 4% in the last one week, but if we look at the record of the last one month, the stock has jumped by 33%. Since the beginning of the year 2026 till now it has increased by more than 102%. At the same time, it has given excellent returns of more than 740% in the last one year. It is the first company in the world to have its manufacturing unit in Sinnar near Nashik (Maharashtra) which has received pre-qualification from the World Health Organization (WHO) and the United Nations Population Fund (UNFPA) to supply male and female condoms. Apart from this, the company also manufactures water-based lubricant jelly and IVD kit.
Company’s confidence increased due to excellent quarterly results
Behind this stormy rise of the stock is the company’s strong business model and continuously increasing profits. Cupid has recently said that its revenue is on track to cross Rs 150 crore in the first quarter of the financial year 2027 (FY27). The company is considering this as one of the best quarterly performances in its history. In view of this excellent start and increasing opportunities at the global level, the management has also increased its future estimates. While earlier the revenue for FY 2027 was estimated at Rs 600 crore, now it has been increased by 10% to Rs 660 crore. The company’s in vitro diagnostics (IVD) business is also growing rapidly. The management believes that with new regulatory approvals and launch of new products, this segment will become a major source of income in the future.
Is it safe to invest at this level?
Harshal Dasani, Business Head, INVasset PMS, believes that the company’s earnings figures are very encouraging, but the share price has also gone up very fast. According to Dasani, after the tremendous rally of the last one year, the stock has incorporated most of the future expectations in its current price. In such a situation, there is very little scope left for the management to make any business mistakes. From a technical point of view, the level of Rs 195 to Rs 200 has become an important support zone, while the stock is facing tough resistance between Rs 220 and Rs 226. The story is strong from a long-term perspective, but at current prices the risk and reward appear to be equal.
Leave a Reply